Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tardive dystonia.

U J Kang1, R E Burke, S Fahn

  • 1Columbia University College of Physicians and Surgeons, New York, New York 10032.

Advances in Neurology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Tardive dystonia, a disabling subtype of tardive dyskinesia, can emerge early during dopamine antagonist treatment. While some drugs offer symptom improvement, complete remission is rare, emphasizing cautious drug use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Frailty on Gait Speed Improvements in Home Health after Hospital Discharge: Secondary Analysis of Two Randomized Controlled Trials.

The Journal of frailty & aging·2024
Same author

Quantitative morphological comparison of axon-targeting strategies for gene therapies directed to the nigro-striatal projection.

Gene therapy·2013
Same author

Animal models of induced apoptotic death in the substantia nigra.

Methods in molecular medicine·2011
Same author

Apoptotic morphology in phenotypically defined dopaminergic neurons of the substantia nigra.

Methods in molecular medicine·2011
Same author

Naturally Occurring Cell Death during Postnatal Development of the Substantia Nigra Pars Compacta of Rat.

Molecular and cellular neurosciences·2009
Same author

GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons.

Journal of neural transmission. Supplementum·2006
Same journal

Future and alternative therapies in Tourette syndrome.

Advances in neurology·2006
Same journal

Behavioral neurosurgery.

Advances in neurology·2006
Same journal

Behavior therapy: other interventions for tic disorders.

Advances in neurology·2006
Same journal

Behavioral treatments for tic suppression: habit reversal training.

Advances in neurology·2006
Same journal

Treatment of aggression in Tourette syndrome.

Advances in neurology·2006
Same journal

Treatment of co-morbid obsessive compulsive disorder, mood, and anxiety disorders.

Advances in neurology·2006
See all related articles

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Tardive dystonia is a movement disorder often associated with dopamine antagonist therapy.
  • Understanding its clinical course and treatment response is crucial for patient management.

Purpose of the Study:

  • To retrospectively review the clinical characteristics and treatment outcomes of tardive dystonia.
  • To evaluate the efficacy of various pharmacological interventions for tardive dystonia.

Main Methods:

  • Retrospective review of 67 patients diagnosed with tardive dystonia.
  • Analysis of patient demographics, drug exposure history, and treatment responses.

Main Results:

  • Tardive dystonia onset occurred across a wide age range, with some patients developing it within a year of dopamine antagonist exposure.

Related Experiment Videos

  • Tetrabenazine and reserpine showed over 50% response rates, while anticholinergics improved symptoms in 46% of patients.
  • Only 5 of 42 patients withdrawn from offending drugs achieved remission; overall clinical improvement was seen in 52%.

    • Conclusions:

    • Tardive dystonia is a persistent and challenging subtype of tardive dyskinesia requiring careful consideration of dopamine antagonist use.
    • Early detection and withdrawal of causative agents are vital, as there is no safe minimum exposure period.
    • While treatments can alleviate symptoms, they rarely lead to complete remission, highlighting the need for judicious prescribing practices.